- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05663866
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
Subcutaneous Methotrexate, Oral Dexamethasone or Oral Montelukast for the Prevention of Infusion Related Reaction Associated With Amivantamab, an EGFR-MET Bispecific Antibody, Among Post-osimertinib Treated EGFRm NSCLC; SKIPPirr, a Phase 2 Study
The purpose of the study is to separately assess the potential of dexamethasone, montelukast and methotrexate administration, prior to amivantamab infusion given through a needle in the vein, to decrease the incidence and/or severity of first-dose infusion related reactions.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Brest, France, 29200
- CHU de Brest - Hopital de la Cavale Blanche
-
Lyon, France, 69008
- Centre Leon Berard
-
Paris, France, 75015
- Hopital Europeen Georges-Pompidou
-
Paris, France, 75014
- Hopital Cochin
-
Rouen, France, 76000
- CHU Rouen Hopital Charles Nicolle
-
Strasbourg, France, 67091
- Nouvel Hopital Civil - CHU Strasbourg
-
-
-
-
-
Cheongju-si, South Korea, 28644
- Chungbuk National University Hospital
-
Gyeonggi-do, South Korea, 10408
- National Cancer Center
-
Incheon, South Korea, 21565
- Gachon University Gil Medical Center
-
Jeollanam-do, South Korea, 58128
- Chonnam National University Hwasun Hospital
-
Seongnam-si, South Korea, 13620
- Seoul National University Bundang Hospital
-
Seoul, South Korea, 05505
- Asan Medical Center
-
-
-
-
-
Barcelona, Spain, 08025
- Hosp. de La Santa Creu I Sant Pau
-
Barcelona, Spain, 8028
- Hosp. Univ. Quiron Dexeus
-
Barcelona, Spain, 08035
- Hosp Univ Vall D Hebron
-
Cáceres, Spain, 10003
- Hosp. San Pedro de Alcantara
-
Jerez de la Frontera, Spain, 11407
- Hosp. de Jerez de La Frontera
-
L'Hospitalet de Llobregat, Spain, 08908
- Inst. Cat. Doncologia-H Duran I Reynals
-
Madrid, Spain, 28041
- Hosp. Univ. 12 de Octubre
-
Madrid, Spain, 28007
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga, Spain, 29010
- Hosp Virgen de La Victoria
-
Palma de Mallorca, Spain, 07120
- Hosp. Univ. Son Espases
-
Santiago de Compostela, Spain, 15706
- Hosp. Clinico Univ. de Santiago
-
Valencia, Spain, 46014
- Hosp. Gral. Univ. Valencia
-
Valencia, Spain, 46009
- Inst. Valenciano de Oncologia
-
Zaragoza, Spain, 50009
- Hosp. Clinico Univ. Lozano Blesa
-
-
-
-
-
Changhua, Taiwan, 500
- Changhua Christian Hospital
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Chung Ho Memorial Hospital
-
Taichung, Taiwan, 40705
- Taichung Veterans General Hospital
-
Tainan, Taiwan, 73657
- Chi-Mei Medical Center, Liouying
-
Taipei, Taiwan, 110
- Taipei Medical University
-
Taipei, Taiwan, 112
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10043
- National Taiwan University Hospital
-
-
-
-
California
-
Fountain Valley, California, United States, 92708
- Compassionate Cancer Care
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists
-
-
Washington
-
Renton, Washington, United States, 98055
- UW Medicine Valley Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant must have advanced or metastatic non-small cell lung cancer (NSCLC)
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
- A female participant using oral contraceptives must use an additional barrier contraceptive method
- A male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person during the study and for 3 months after receiving the last dose of study treatment, oral lazertinib and intravenous (IV) Amivantamab
- Each participant, or legally authorized representative, where allowed, must sign an informed consent form (ICF) indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
- Progressed on or after prior treatment with osimertinib and platinum-based chemotherapy. Prior use of first-or-second generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is allowed if administered prior to osimertinib
- Previously identified EGFR-mutated non-small cell lung cancer (NSCLC) (EGFR Exon19 deletion or L858R) (identified locally in a Clinical Laboratory Improvement Amendments [CLIA]-certified laboratory [or equivalent])
Exclusion Criteria:
- Participant has a medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
- Prior treatment with anti PD-1 or anti PD-L1 antibody within 6 weeks of planned first dose of study treatment or immune-mediated rash from checkpoint inhibitors that has not resolved prior to enrollment
- Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have completed definitive therapy, are not on steroids, and have a stable clinical status for at least 2 weeks prior to study treatment are allowed. If brain metastases are diagnosed on Screening imaging, the participant may be enrolled, or rescreened for eligibility, after definitive treatment if above criteria are met
- Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) version 5.0 Grade 1 or baseline level (except for alopecia [any grade], Grade less than or equal to [<=] 2 peripheral neuropathy, and Grade <=2 hypothyroidism stable on hormone replacement therapy)
- Prior treatment with amivantamab or lazertinib
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Background Anti-cancer Therapy with Amivantamab Plus Lazertinib
Participant will receive following treatments in 4 different cohorts prior to administration of combination therapy of IV Amivantamab and oral Lazertinib (anti-cancer regimen): dexamethasone dose-1 in Cohort A; dexamethasone dose-2 in Cohort A2; montelukast in Cohort B; and methotrexate in Cohort C. |
Dexamethasone will be administered orally. Lazertinib tablets will be administered orally.
Other Names:
Montelukast will be administered orally. Methotrexate will be administered subcutaneously. Amivantamab will be administered intravenously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1
Time Frame: Cycle 1 Day 1 (each cycle of 28 days)
|
Percentage of participants with IRRs at Cycle 1 Day 1 was reported. IRRs were defined as IRR events with onset time within 24 hours of the start of the first amivantamab infusion and prior to the start of amivantamab infusion on Cycle 1 Day 2. IRR included chills, dyspnea, flushing, nausea, chest discomfort, vomiting, tachycardia, hypotension, and fever. IRRs that occurred on Cycle 1 Day 2 pre-infusion were considered under Cycle 1 Day 1. |
Cycle 1 Day 1 (each cycle of 28 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percentage of Participants With Adverse Events of Infusion-related Reactions (IRRs) During Cycle 1 Day 1
Time Frame: Cycle 1 Day 1 (each cycle of 28 days)
|
Cycle 1 Day 1 (each cycle of 28 days)
|
|
Percentage of Participants With Adverse Events (AEs) of Infusion-related Reactions (IRRs) as Per Severity up to End of Cycle 3 (Cycle 3 Day 28)
Time Frame: From Cycle 1 Day 1 up to Cycle 3 Day 28 (each cycle of 28 days)
|
From Cycle 1 Day 1 up to Cycle 3 Day 28 (each cycle of 28 days)
|
|
Percentage of Participants With IRRs up to End of Treatment (EOT)
Time Frame: From Cycle 1 Day 1 (each cycle of 28 days) up to 27.3 months
|
From Cycle 1 Day 1 (each cycle of 28 days) up to 27.3 months
|
|
Percentage of Participants With Other Adverse Events (AEs): Non-IRRs
Time Frame: From Cycle 1 Day 1 (each cycle of 28 days) up to 28.3 months
|
From Cycle 1 Day 1 (each cycle of 28 days) up to 28.3 months
|
|
Duration of Infusion Time for Pre-amivantamab Infusion Medications, IV Amivantamab Infusion, and Post-amivantamab Infusion Medications on Cycle 1 Day 1
Time Frame: Cycle 1 Day 1 (each cycle of 28 days)
|
Cycle 1 Day 1 (each cycle of 28 days)
|
|
Percentage of Participants Completing Amivantamab Infusion Within 4 Hours on Cycle 1 Day 1
Time Frame: Up to 4 hours on Cycle 1 Day 1 (each cycle of 28 days)
|
Up to 4 hours on Cycle 1 Day 1 (each cycle of 28 days)
|
|
Overall Response Rate (ORR)
Time Frame: From Cycle 1 Day 1 (each cycle of 28 days) up to 28.3 months
|
From Cycle 1 Day 1 (each cycle of 28 days) up to 28.3 months
|
|
Duration of Response (DOR)
Time Frame: From Cycle 1 Day 1 (each cycle of 28 days) up to 28.3 months
|
From Cycle 1 Day 1 (each cycle of 28 days) up to 28.3 months
|
Collaborators and Investigators
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Polycyclic Compounds
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Pterins
- Pteridines
- Pregnadienetriols
- Aminopterin
- Dexamethasone
- Methotrexate
- amivantamab
- lazertinib
- montelukast
Other Study ID Numbers
- CR109305
- 2022-000974-25 (EudraCT Number)
- 61186372NSC2005 (Other Identifier: Janssen Research & Development, LLC)
- 2023-506578-11-00 (Registry Identifier: EUCT number)
- 2023 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.